Physician profile
Christopher C Daigle
NPI 1861503567
$11,810.29
in general payments reported to CMS, 2019-2025
16 companies · $344 in 2025
The $344 reported for 2025 was less than what a typical Pulmonary Disease provider received nationally (typical 2025 total: $500).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $67.49 · 2020: $45.45 · 2021: $18.56 · 2022: $70.25 · 2023: $8,300 · 2024: $2,964 · 2025: $344.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Education: $10K · Food and Beverage: $1,326.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Education | $10,282.58 |
| Food and Beverage | $1,325.96 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Intuitive Surgical, INC. | $10,357.71 | 2023-2024 | Davinci Xi |
| Astrazeneca Pharmaceuticals LP | $346.42 | 2020-2024 | Tezspire, Breztri, Airsupra |
| Glaxosmithkline, LLC. | $300.87 | 2019-2025 | Nucala, Trelegy Ellipta |
| Inspire Medical Systems, INC. | $182.41 | 2025 | Inspire |
| Inari Medical, INC. | $179.10 | 2023 | Ct Thrombectomy System Kit, Flowtriever Catheter, S |
| Genzyme Corporation | $94.44 | 2024-2025 | |
| Harmony Biosciences LLC | $52.79 | 2023-2024 | Wakix |
| Regeneron Healthcare Solutions, INC. | $52.54 | 2023-2024 | Dupixent |
| Jazz Pharmaceuticals INC. | $50.69 | 2024-2025 | |
| Pulmonx Corporation | $44.89 | 2025 | Zephyr Delivery Catheter, Pulmonx Chartis Tablet Console, Chartis Catheter |
| W. L. Gore & Associates, INC. | $37.20 | 2019 | |
| United Therapeutics Corporation | $32.59 | 2021-2023 | Tyvaso |
| Itamar Medical INC | $20.05 | 2022 | |
| Mylan Specialty L.P. | $19.84 | 2023 | Yupelri |
| Grifols USA, LLC | $19.71 | 2022 |
Show all 16 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Idorsia Pharmaceuticals US INC | $19.04 | 2023 | Quviviq |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Christopher Daigle listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.